2025
Biomarker testing of lung cancer in North America versus globally.
Smeltzer M, King J, Connolly C, Brunson K, Chau M, Chen S, Kerpel-Fronius A, Lantuejoul S, Mohan A, Plaxco A, Rice J, Basu Roy U, Santos R, Woodard G, Wynes M, Young A, Yatabe Y, Soo R, Kelly K. Biomarker testing of lung cancer in North America versus globally. Journal Of Clinical Oncology 2025, 43: 8541-8541. DOI: 10.1200/jco.2025.43.16_suppl.8541.Peer-Reviewed Original ResearchInternational Association for the Study of Lung CancerHigher incomeKey barriersBiomarker testingLung cancerPatient outcomesTesting practicesIdentified key barriersMiddle income countriesImpact patient outcomesBiomarker testing practicesStudy of Lung CancerSuboptimal due to lackChi-square testEarly-stage patientsEarly-stage LCFocus groupsAdvocacy partnersMedical educationLMICsIncome countriesMulti-disciplinary committeeSignificant disparitiesTurnaround timeMeasure improvement
2024
The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review
Zolfaghari E, Dhanasopon A, Woodard G. The evolving landscape of adjuvant therapy in T1-T2N0 resected non-small cell lung cancer: a narrative review. Journal Of Thoracic Disease 2024, 0: 0-0. PMID: 39831209, PMCID: PMC11740046, DOI: 10.21037/jtd-24-245.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorEarly-stage non-small cell lung cancerAnaplastic lymphoma kinaseAdjuvant therapyCell lung cancerEarly-stage patientsSurgical resectionOverall survivalAdjuvant chemotherapyLung cancerSurvival benefit of adjuvant therapyAdjuvant platinum-based chemotherapyBenefit of adjuvant therapyHigh-risk pathologic featuresStage IB tumorsNational Clinical Trials RegistryPlatinum-based chemotherapyHigh-risk featuresCirculating tumor DNALandscape of adjuvant therapyLung cancer recurrenceGrowth factor receptorClinical Trials RegistryAdjuvant osimertinib
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply